Retatrutide Research

Retatrutide vs Mounjaro, Ozempic and Wegovy

UKPWritten & reviewed by William Heath · Editor, UK Peptides research library3 min readLast reviewed 2026-08-314 cited sources

The short answer

Ozempic and Wegovy are semaglutide, which engages GLP-1. Mounjaro and Zepbound are tirzepatide, which adds GIP. Retatrutide adds glucagon on top and has no brand name because it is approved nowhere. Reported reductions rise across the three, but come from separate trials, so the comparison is indirect.

Key facts

Ozempic / Wegovy
Semaglutide; GLP-1 only; approved
Mounjaro / Zepbound
Tirzepatide; GIP + GLP-1; approved
Retatrutide
All three receptors; no brand name
SURMOUNT-5 head-to-head
Tirz 20.2% vs sema 13.7%
TRIUMPH-1
28.3% at 80 weeks (12 mg)
Direct comparison
TRIUMPH-5, completing Nov 2026

Mounjaro, Ozempic, Wegovy: which name is which molecule

Mounjaro and Zepbound are the same molecule (tirzepatide) licensed under two names, the first for type 2 diabetes and the second for weight management. Ozempic and Wegovy are semaglutide, split along the same line. Retatrutide has no brand name at all, because a brand name is something a medicine acquires at approval and retatrutide is approved nowhere; in the literature it is LY3437943. So "retatrutide vs Mounjaro" is retatrutide against tirzepatide, and "retatrutide vs Ozempic" is retatrutide against semaglutide. The comparisons below use the molecule names for that reason.

The one comparison that is direct

SURMOUNT-5 randomised 751 adults to tirzepatide or semaglutide for 72 weeks: 20.2% against 13.7%. Same population, same duration, same trial. That is the strongest form of evidence and it establishes the dual agonist's advantage over the single one.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

The comparison that is not

Retatrutide's 28.3% comes from TRIUMPH-1 at 80 weeks; tirzepatide's figures come from SURMOUNT trials at 72. Different populations, different durations, and estimands that may differ. Placing 28.3% next to 20.9% suggests a precision the data does not support. The direction is probably right, the magnitude of the gap is not established.

What will settle it

TRIUMPH-5, registered as NCT06662383, randomises 800 adults to retatrutide or tirzepatide directly, with primary completion in November 2026. Because both are Lilly molecules on modified GIP scaffolds, it isolates the glucagon arm's contribution about as cleanly as a trial can.

The regulatory difference that matters most

Semaglutide and tirzepatide are licensed medicines with marketing authorisations. Retatrutide is investigational and approved nowhere; Lilly has signalled an FDA filing for Q1 2027. Comparing effect sizes across the three obscures the fact that two can be prescribed and one cannot.

Tolerability moves too

More receptors has consistently meant more gastrointestinal burden. TRIUMPH-1 reported 11.3% discontinuation due to adverse events on the 12 mg arm against 4.9% on placebo. SURMOUNT-5 reported the opposite pattern between its two arms (tirzepatide better tolerated than semaglutide on GI discontinuation) so the relationship is not perfectly monotonic.

And none of this concerns research material

Semaglutide and tirzepatide are prescription medicines. Retatrutide is an investigational compound in registered trials. Material supplied for laboratory research is not related to any of them, is not an alternative to any of them, and none of these figures describes it.

Quick reference

Ozempic / WegovyMounjaro / ZepboundRetatrutide
MoleculeSemaglutideTirzepatideLY3437943
ReceptorsGLP-1GIP + GLP-1GIP + GLP-1 + glucagon
Molecular weight4,114 Da4,813 Da~4,731 Da
StatusApprovedApprovedInvestigational
Head-to-head13.7% (SURMOUNT-5)20.2% (SURMOUNT-5)TRIUMPH-5 pending

Frequently asked questions

Is retatrutide more effective than tirzepatide?

Its reported figures are higher, but from separate trials with different populations and durations. TRIUMPH-5 tests it directly, completing November 2026.

Which can actually be prescribed?

Semaglutide and tirzepatide hold marketing authorisations. Retatrutide is investigational and approved nowhere.

Does more receptors always mean better tolerated?

No, generally the opposite. Though SURMOUNT-5 found tirzepatide better tolerated than semaglutide on GI discontinuation, so it is not a strict rule.

Is retatrutide better than Mounjaro?

Mounjaro is tirzepatide. Retatrutide's reported 28.3% at 80 weeks is higher than tirzepatide's 20.2% in SURMOUNT-5, but those are different trials with different populations and durations, so the gap is not established. TRIUMPH-5 compares them directly and completes in November 2026.

Is retatrutide the same as Ozempic?

No. Ozempic is semaglutide, a GLP-1 agonist that has been licensed since 2017. Retatrutide is a different molecule engaging three receptors, and it holds no marketing authorisation anywhere.

Is retatrutide better than semaglutide?

Semaglutide is the molecule in Ozempic and Wegovy. Retatrutide's reported reductions are larger, but semaglutide's come from separate trials and semaglutide is licensed while retatrutide is not. No trial has compared the two directly.

Is retatrutide stronger than Mounjaro?

On reported weight reduction the retatrutide figures are higher, but no head-to-head trial has reported. Tolerability moves the other way: TRIUMPH-1 reported 11.3% discontinuation for adverse events on the 12 mg arm.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

William Heath · Editor, UK Peptides research library

William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.

More Retatrutide Research articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.